Core Viewpoint - Lin Qingxuan, known as the "first stock of high-end domestic skincare," officially listed on December 30, 2025, with a market capitalization of HKD 11.87 billion, reflecting a 9.3% increase from its IPO price of HKD 77.77 per share [1][19]. Investment Activities - In 2025, L'Oréal Group completed over 18 investments globally, with 7 specifically targeting the Chinese market, showcasing a proactive investment strategy in a cautious environment [1][26]. - L'Oréal's investment in Lin Qingxuan was made through the Kewen Future Fund, acquiring 691,620 shares for HKD 105 million, representing a 2.75% stake [1][22]. - The investment in Lin Qingxuan is part of L'Oréal's broader strategy, which included investments in four Chinese beauty brands within six months, surpassing the total number of investments made in the previous three years [1][6][25]. Market Trends - The high-end beauty market in China is experiencing a slowdown, with a projected compound annual growth rate of -3% from 2021 to 2024, leading to a strategic focus on high-end investments by L'Oréal [11][28]. - L'Oréal's financial report for the first three quarters of 2025 indicated modest growth across its various divisions, with the high-end cosmetics division showing the slowest growth [11][28]. Strategic Focus - L'Oréal's investment strategy emphasizes both consolidating its high-end market position and betting on high-growth segments, reflecting a dual approach of defense and offense [9][28]. - The company is diversifying its high-end portfolio by acquiring brands like Jacquemus and Amouage, while also investing in emerging technologies and biotech firms to enhance its product offerings [29][30][32]. Investment Philosophy - L'Oréal's shift from acquiring established brands to investing in innovative local brands indicates a strategic evolution towards nurturing local market dynamics and capturing emerging consumer trends [34]. - The company is focusing on upstream investments in biotechnology and sustainable materials, aiming to strengthen its competitive edge through technological advancements [32][34].

Core Viewpoint - Lin Qingxuan, a high-end domestic skincare brand, officially listed on the Hong Kong Stock Exchange on December 30, 2025, with a closing price of HKD 85 per share, a 9.3% increase from the issue price of HKD 77.77, resulting in a market capitalization of approximately HKD 11.9 billion [2][28]. Group 1: Company Overview - Lin Qingxuan's flagship product, the Camellia Oil, has sold over 45 million bottles since its launch in 2014, averaging 4.29 million bottles sold annually [8][28]. - The company has a diverse product line with 188 SKUs, including essential oils, creams, toners, lotions, serums, masks, and sunscreens, with essential oils, creams, serums, and sunscreens being the four core categories [5][32]. - The pricing of Lin Qingxuan's products ranges from 80 to 2000 RMB, with the 50ml Camellia Oil priced at 799 RMB and a New Year gift set priced at 1443 RMB [7][34]. Group 2: Financial Performance - From 2022 to 2024, Lin Qingxuan's revenue grew from 691 million RMB to 1.21 billion RMB, with a compound annual growth rate of 32.5%. In the first half of 2025, the company achieved revenue of 1.052 billion RMB and a net profit of 182 million RMB [8][35]. - The gross margin of Lin Qingxuan has been increasing, reaching 82.5% in 2024, with the gross margin for the Camellia Oil at 86.2%, comparable to high-end liquor margins [10][38]. - The marketing expenses over three and a half years totaled approximately 1.121 billion RMB, with a significant portion of the workforce (85.2%) dedicated to sales and marketing [11][12][39]. Group 3: Marketing Strategy - The founders, Sun Laichun and Sun Fuchun, actively engage in live streaming and social media to promote the brand, creating a unique "Lin Qingxuan family IP matrix" that includes family members participating in content creation [4][30]. - The company has accumulated around 7.96 million followers on Tmall and over 1.66 million on Douyin, with significant sales during promotional events [19][46]. - Lin Qingxuan has faced challenges with advertising compliance, receiving fines for misleading claims about product efficacy, which highlights the importance of regulatory adherence in marketing strategies [20][47]. Group 4: Market Position - Lin Qingxuan ranks first among all high-end domestic skincare brands in China and is the only domestic brand among the top 15 high-end skincare brands, including international competitors [8][34]. - The company has expanded its offline presence, with 554 stores nationwide, primarily located in shopping centers, reinforcing its high-end brand image [19][46]. - Despite facing consumer complaints regarding product efficacy and pricing, the overall market sentiment towards Lin Qingxuan remains positive, with significant backing from institutional investors [27][51].

Core Insights - Lin Qingxuan has officially listed on the Hong Kong Stock Exchange, becoming the first domestic high-end skincare brand to do so, with stock code 2657.HK [3] - The company has established a carbon-neutral research and manufacturing base in Shanghai, marking it as the first cosmetics factory designed strictly according to carbon-neutral standards [1] Company Performance - Lin Qingxuan's revenue has shown significant growth, increasing from 691 million yuan in 2022 to an expected 1.21 billion yuan in 2024, with a compound annual growth rate (CAGR) of 32.3% [6] - In the first half of 2025, the company reported a revenue of 1.052 billion yuan, a year-on-year increase of 98.3%, with a corresponding net profit of 182 million yuan, reflecting a growth of 109.8% [6] - The gross margin for the first half of 2025 reached 82.4%, up from 78% in 2022 [6] Product Highlights - The core product, Camellia Oil, has contributed significantly to revenue, accounting for 45.5% of total income in the first half of 2025 [4] - New product launches, such as the Camellia Anti-Wrinkle Peptide Essence Water, achieved sales of over 100 million yuan within three months of launch [4] - The company has a complete product matrix including essence oils, creams, toners, lotions, serums, masks, and sunscreens [3] Market Potential - The Chinese cosmetics market is projected to reach 688.6 billion yuan in 2024, with skincare products making up 461.9 billion yuan, and anti-wrinkle products expected to grow at a CAGR of 15% from 2019 to 2024 [7] - The anti-wrinkle skincare segment is anticipated to reach a market size of 119.8 billion yuan in 2024, representing 25.9% of the skincare market [7] Competitive Position - Lin Qingxuan ranks as the 10th high-end skincare brand in China, with a market share of 2.2%, amidst a competitive landscape dominated by foreign brands [12] - The company has established a strong research and development foundation, holding over 600 formula patents and 87 patents, including 46 invention patents [11] Strategic Investments - The company has attracted strategic investments from major players, including L'Oréal, which acquired a 2.75% stake through its fund [13] - Lin Qingxuan's IPO raised over 1 billion HKD, with plans to use the funds for research innovation, channel expansion, and brand development [14] Industry Support - Recent policies in Shanghai aim to promote high-quality development in the cosmetics industry, providing financial support for new raw materials and brand promotion initiatives [14] - The goal is to cultivate companies with market values of 50 billion yuan and 10 billion yuan within three years, indicating a supportive environment for growth [14]

Core Viewpoint - The successful listing of Lin Qingxuan marks the emergence of the first high-end domestic skincare stock in China, symbolizing a significant milestone in the brand's 22-year journey from Shanghai to the international capital market [1]. Group 1: Company Growth and Milestones - Lin Qingxuan's IPO price was set at HKD 77.77 per share (approximately RMB 70.05), with an opening price of HKD 85 and a peak of HKD 91, resulting in a total market capitalization of HKD 124.02 billion by 13:10 [1]. - The company is projected to achieve over RMB 1 billion in revenue in the first half of 2025, reflecting a substantial year-on-year growth of 98.30%, and aims to join the RMB 2 billion club by the end of this year [1]. - The brand's journey began in 2003 with the creation of its first handmade soap, and it has since sold over 20 billion units, with its core product, camellia oil, achieving cumulative sales of over 45 million bottles [1]. Group 2: Brand Philosophy and Strategy - Lin Qingxuan's founder, Sun Laichun, chose a name that reflects Chinese culture rather than following the trend of adopting Western names, which has proven beneficial as domestic consumer preferences have shifted towards local brands [4][5]. - The brand's focus on camellia oil since 2012, despite the dominance of international brands in the high-end skincare market, has significantly contributed to its revenue growth, with camellia oil products accounting for over 10 billion in revenue by 2025 [5]. - Lin Qingxuan emphasizes quality over speed in product development, with extensive time spent on research and development to ensure the natural efficacy of its products [8][10]. Group 3: Resilience and Adaptation - The company faced a critical challenge during the COVID-19 pandemic in 2020, where all offline stores were closed, leading to a near-zero performance for over 1,000 sales staff [14][15]. - Instead of resorting to layoffs, Lin Qingxuan's management opted for salary reductions and encouraged employees to adapt, which helped the company survive the crisis [20]. - The brand's commitment to its mission and values played a crucial role in navigating through difficult times, demonstrating the importance of corporate culture in crisis management [20]. Group 4: Strategic Decisions and Market Positioning - Lin Qingxuan made a strategic decision to discontinue its hand soap business, which generated over RMB 100 million in GMV, to focus on the higher potential camellia oil project, despite initial backlash [22]. - The company has maintained a high-end positioning by avoiding low-priced products and investing heavily in research and development, with the R&D budget since 2022 surpassing the total of the previous ten years [22][23]. - Lin Qingxuan's approach to market positioning emphasizes deep specialization in core products, which has allowed it to carve out a unique space in the high-end skincare market [23]. Group 5: Future Outlook - The listing on the Hong Kong Stock Exchange is viewed as a starting point for Lin Qingxuan's multi-brand and global expansion strategy [25]. - The brand's success story serves as an inspiration for emerging domestic brands, highlighting that with a focus on core values and quality, local brands can thrive in the competitive high-end market [25][26].

Core Viewpoint - The Hong Kong IPO market remains vibrant as Lin Qingxuan, known as the "first domestic high-end skincare stock," successfully listed on December 30, 2025, with its stock price surging over 16% on the first day, closing at 85 HKD, indicating strong market confidence in its growth potential [1]. Group 1: Company Overview - Lin Qingxuan was founded in 2003, initially offering affordable skincare products, and transitioned to high-end skincare by focusing on camellia oil products starting in 2012 [2]. - The company has established a strong technological barrier through its unique "cell-level anti-wrinkle" technology, which has positioned it as the leading domestic high-end skincare brand in China by retail sales as of 2024 [2][4]. Group 2: Product Innovation and Technology - Lin Qingxuan has developed patented ingredients such as Camellia Super Peptide and Camellia Super Collagen, which provide skin repair benefits, including enhancing elasticity and reducing fine lines [3]. - The company collaborates with academic institutions to establish a "Cell-Level Anti-Wrinkle Joint Research Laboratory," ensuring continuous innovation and application of cutting-edge research [3]. Group 3: Financial Performance - From 2022 to 2024, Lin Qingxuan's revenue grew significantly, reaching 6.91 billion CNY in 2022, 8.05 billion CNY in 2023, and projected at 12 billion CNY in 2024, with a compound annual growth rate of 32.3% [5]. - The net profit transitioned from a loss of 5.93 million CNY in 2022 to a profit of 8.45 million CNY in 2023, and further increased by 121.1% to 187 million CNY in 2024, indicating a strong upward trend in profitability [6]. Group 4: Market Reception and Product Success - The star product, Camellia Essence Oil, has sold over 45 million bottles since its launch in 2014, contributing 45.5% of the revenue in the first half of 2025, with a remarkable growth rate of 176% [6]. - New product launches have also performed exceptionally well, with the Camellia Anti-Wrinkle Peptide Microbead Essence Water achieving over 700 million CNY in sales during its first live broadcast [7]. Group 5: Long-term Investment Value - Lin Qingxuan has evolved from a successful brand story to a commercially viable entity with strong self-sustaining capabilities and long-term investment value, supported by its robust financial performance and technological barriers [8].

Core Viewpoint - The Hong Kong IPO market remains vibrant as Lin Qingxuan, known as the "first high-end domestic skincare stock," successfully listed on December 30, 2025, with its stock price surging over 16% on the first day, closing at 85 HKD, indicating strong market confidence in its growth potential [1]. Group 1: Company Overview - Lin Qingxuan was founded in 2003, initially offering affordable skincare products before pivoting to high-end skincare with a focus on camellia flower ingredients starting in 2012 [2]. - The company has established a strong technological barrier through deep research and development, leading to its position as the top high-end domestic skincare brand in China by retail sales in 2024 [2][4]. Group 2: Product Innovation and Technology - Lin Qingxuan has developed patented ingredients such as Camellia Extract and various peptides, which provide skin repair benefits, including enhancing elasticity and reducing fine lines [3]. - The company emphasizes "cell-level anti-wrinkle" technology, supported by collaborations with academic institutions and the establishment of a dedicated research laboratory [3][4]. Group 3: Financial Performance - Lin Qingxuan has shown impressive revenue growth from 6.91 billion CNY in 2022 to an expected 12 billion CNY in 2024, with a compound annual growth rate of 32.3% [5]. - The company transitioned from a loss of 5.93 million CNY in 2022 to a profit of 8.45 million CNY in 2023, with net profit reaching 1.87 billion CNY in 2024, reflecting a growth of 121.1% year-on-year [6]. Group 4: Market Reception and Sales Performance - The star product, Camellia Essence Oil, has sold over 45 million bottles since its launch in 2014, contributing 45.5% of the company's revenue in the first half of 2025, with a remarkable growth rate of 176% [6][7]. - New product launches have also performed exceptionally well, with the Camellia Anti-Wrinkle Peptide Microbead Essence Water achieving over 700 million CNY in sales during its first live broadcast [7]. Group 5: Long-term Investment Value - Lin Qingxuan's strong financial performance, robust technological barriers, and impressive market debut position it as a business entity with significant self-sustaining capabilities and long-term investment value [8].

Core Viewpoint - Lin Qingxuan, a high-end skincare brand from China, officially listed on the Hong Kong Stock Exchange, becoming the first domestic high-end skincare stock, amidst fierce competition in the skincare market [1][3]. Group 1: Company Overview - Founded in 2003, Lin Qingxuan initially focused on basic skincare products but pivoted to high-end offerings centered around camellia oil after discovering its benefits [4]. - The brand has established itself as a leader in the high-end skincare segment, particularly with its camellia oil products, which have dominated the market for over a decade [4][7]. Group 2: Financial Performance - Lin Qingxuan's revenue grew from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with a compound annual growth rate of 32.3%, surpassing the industry average [5]. - In the first half of 2025, revenue surged to 1.052 billion yuan, nearly doubling from the same period in 2024, while adjusted net profit increased by 117.4% to 200 million yuan [5]. Group 3: Market Position - By 2024, Lin Qingxuan ranked 13th among all high-end skincare brands in China, holding a 1.4% market share, and is the only domestic brand in the top 15 [7]. - The brand is positioned as the leading domestic high-end skincare brand in China [7]. Group 4: Innovation and R&D - Lin Qingxuan has developed over 600 formulas and 87 patents, focusing on advanced extraction and purification techniques to enhance its product efficacy [8]. - The company integrates traditional herbal wisdom with modern cellular-level skincare technology, establishing a comprehensive solution for anti-wrinkle skincare [9][10]. Group 5: Future Strategy - Following its IPO, Lin Qingxuan aims to enhance its brand presence and expand its retail footprint while continuing to invest in R&D for skincare technologies [11][12]. - The company plans to leverage its capital to strengthen its core products and deliver exceptional skincare experiences to consumers [12].

Core Viewpoint - Lin Qingxuan has officially listed on the Hong Kong Stock Exchange, becoming the first high-end domestic skincare brand in the Hong Kong market, focusing on anti-wrinkle and firming skincare products with a commitment to quality and supply chain control [1][2]. Group 1: Company Overview - Lin Qingxuan specializes in high-end skincare products, particularly in the anti-wrinkle and firming segment, utilizing natural camellia flower as a core ingredient [1]. - The company has established a complete value chain from seedling cultivation to production and sales, ensuring product quality and stable supply [1]. - As of 2024, Lin Qingxuan ranks first among domestic high-end skincare brands and is the only domestic representative among China's top 15 high-end skincare brands [1]. Group 2: Financial Performance - From 2022 to 2024, Lin Qingxuan's revenue is projected to grow from 690 million to 1.21 billion, with a compound annual growth rate of 32.3% [2]. - In the first half of 2025, revenue surged by 98.3% year-on-year, reaching 1.052 billion, while adjusted net profit increased by 117.4% to 200 million [2]. Group 3: Industry Impact and Future Outlook - Lin Qingxuan's listing is seen as a catalyst for the high-end transformation of domestic beauty brands, encouraging more brands to enhance their R&D and establish core technologies [2]. - The company plans to use the funds raised from the IPO to improve production efficiency, advance global branding, and digital transformation, aiming for sustained high growth and international recognition [3]. - The founder emphasizes ongoing investment in dermatology, botany, and cutting-edge skincare technology, alongside brand development and retail expansion to enhance customer experience and shareholder value [3].

Core Insights - Six companies, including Yingxi Intelligent, Woan Robotics, Linqingxuan, Meilian Holdings, Xunce, and Wuyi Vision, simultaneously listed on the Hong Kong Stock Exchange on December 30, marking the end of the 2025 IPO season and the first time in five years that six companies have listed on the same day [1][10] Group 1: Market Activity - The Hong Kong IPO market saw a significant increase in activity in 2025, with a total of 117 companies listed and a total fundraising amount of 285.7 billion HKD, making it the highest globally [14] - The average daily trading volume reached a historical high, indicating a robust market environment [14] - The successful listing of six companies on the same day is expected to lead to continued strong IPO activity in 2026, with predictions of around 160 new listings and total fundraising of at least 300 billion HKD [15] Group 2: Company Performances - All six companies listed on December 30 performed well, with no company experiencing a drop below the issue price on the first day of trading [10] - Wuyi Vision and Yingxi Intelligent had the highest first-day gains, with increases of 29.90% and 24.66%, respectively [10] - Yingxi Intelligent's public offering saw a subscription rate of 1427.37 times, indicating strong investor interest [10] Group 3: Company Highlights - Woan Robotics, a leader in AI-driven household robotics, emphasized its commitment to innovation and responsibility in the AI industrial revolution during its listing speech [8] - Linqingxuan, a domestic skincare brand, announced plans for global expansion and increased investment in research and development following its listing [9] - Xunce, a provider of real-time data infrastructure, expressed its belief in data intelligence as a core driver of high-quality industrial development [9] Group 4: Investment Insights - High-profile investors, such as Hillhouse Capital, backed both Yingxi Intelligent and Woan Robotics, highlighting a trend of AI applications in complex industrial scenarios [13] - Wuyi Vision is noted as the first Physical AI company to list in China, showcasing its unique capabilities in connecting the digital and physical worlds [13]

Group 1: IPO Overview - Six companies, including Yingxi Intelligent, Woan Robotics, Linqingxuan, Meilian Holdings, Xunce, and Wuyi Vision, simultaneously listed on the Hong Kong stock market on December 30, marking the end of the 2025 IPO season and the first time in five years that six companies have listed on the same day [1][2] - The last occurrence of six or seven companies listing on the same day was in July 2020, with the peak being eight companies on July 12, 2018 [1] Group 2: Market Reception - All six companies performed well on their first day, with no company experiencing a drop below the issue price. Wuyi Vision and Yingxi Intelligent had the highest gains, at 29.90% and 24.66% respectively [4] - Yingxi Intelligent's public offering saw a subscription rate of 1427.37 times, indicating strong market interest [4] Group 3: Company Highlights - Woan Robotics is a leading provider of AI-enabled home robotics, focusing on AI machine vision and control technologies, and aims to lead the industrial revolution in AI [3][6] - Linqingxuan, a domestic cosmetics brand, plans to enhance its global presence and invest in R&D for skincare technology following its listing [3] - Xunce, a provider of real-time data infrastructure, emphasizes the importance of data intelligence in driving high-quality industrial development [3] Group 4: Market Trends - The Hong Kong IPO market saw a significant increase in financing, with a total of 117 companies listed in 2025, raising 285.7 billion HKD, making it the top global market for IPO financing [7][8] - The interest in IPOs is expected to continue into 2026, with predictions of around 160 new listings and total financing exceeding 300 billion HKD [8]